This study aims to improve the bioactivity response of osteoblasts attachment and proliferation on commercial pure titanium surface by the mixture of nanocomposite coating material of 70% TiO 2 (rutile 10-30 nm, Sky Spring Nanomaterials, USA) and 30% ZrO 2 (20-30 nm, Sky Spring Nanomaterials, USA). This may increase the likelihood of developing the modified implant surface by electrophoretic deposition and the dipping methods of nanocomposite mixture to enhance the surface bioactivity and promote bone formation. Three groups of commercially pure titanium: one uncoated group and two coated groups with nanocomposite mixture of different coating techniques; one group for electro photic deposition technique (EPD); and one group for dip technique. The bioactivity evaluation of cell cultures, isolation of osteoblast cells from calvaria and long limbs of 3-4 days neonatal rats to evaluate the attachment and the proliferation assay in 4 and 8 days of incubation periods for each group. However, osteoblast cells attachment and proliferation showed the least attached and proliferated cells in uncoated samples, while the EPD coated sample showed the highest.
Squamous cell carcinoma of larynx is one of the most common malignant neoplasms of the head and neck. Carcinoma of the larynx represents 2.2% of all cancers in men and 0.4% in women, with predilection of old aged men of more than 50 years rather than women. Smoking is the main risk factor. Alcohol, nutritional factors and virus as Human papillomavirus (HPV) play a role in the pathogenesis of laryngeal carcinoma. Programmed death-ligand (PDL1) is the new introduced marker that be considered as treatment target nowadays in addition to its prognostic application. Aims of study: This study was designed to assess the predictive the role of PDL1 in laryngeal squamous cell carcinoma in comparison with other prognostic markers (P53 and Ki-67). Results: The current study revealed that PDL1 expression was reported in about 20 % of laryngeal squamous cell carcinoma and 10% in premalignant, while it was negative in benign laryngeal lesions. Others markers; P53 protein was shown to be positive in around 42.5 percent of laryngeal squamous cell carcinomas, 40 percent of premalignant laryngeal lesions, and about 12 percent of benign laryngeal lesions.
Squamous cell carcinoma of larynx is one of the most common malignant neoplasms of the head and neck. Carcinoma of the larynx represents 2.2% of all cancers in men and 0.4% in women, with predilection of old aged men of more than 50 years rather than women. Smoking is the main risk factor. Alcohol, nutritional factors and virus as Human papillomavirus (HPV) play a role in the pathogenesis of laryngeal carcinoma. Programmed death-ligand (PDL1) is the new introduced marker that be considered as treatment target nowadays in addition to its prognostic application. Aims of study: This study was designed to assess the predictive the role of PDL1 in laryngeal squamous cell carcinoma in comparison with other prognostic markers (P53 and Ki-67).Results: The current study revealed that PDL1 expression was reported in about 20 % of laryngeal squamous cell carcinoma and 10% in premalignant, while it was negative in benign laryngeal lesions. Others markers; P53 protein was shown to be positive in around 42.5 percent of laryngeal squamous cell carcinomas, 40 percent of premalignant laryngeal lesions, and about 12 percent of benign laryngeal lesions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.